Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05655546 · ClinicalTrials.gov registry record · NA
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
A NA study, sponsored by Scripps Translational Science Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2,117
- Enrollment target
NCT05655546: Clinical Trial NA study, sponsored by Scripps Translational Science Institute.
NCT05655546 is a NA study that was terminated before completion, run by Scripps Translational Science Institute. The registered enrollment target is 2,117 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05655546, a NA study, was terminated before completion, sponsored by Scripps Translational Science Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2,117 participants
- Enrollment target
Study Summary
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those who are 65 years and older. They will also analyze whether these efforts lower the cost of care compared to standard of care.
Primary Outcome
In claims data COVID hospital admissions were defined as: claim type is "HOSP" or "Institutional" or location display contains "inpatient" with COVID diagnosis or COVID procedure or COVID medication in the same medical episode. In survey data, participants were asked to self-report COVID hospitalizations.
Interventions
- OTHER Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,117 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2024-06-20 |
| Phase | NA |
Why NCT05655546 stopped before completion
NCT05655546 is an interventional study that assigns participants to a tested intervention. Its 2,117 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 1 intervention - of which Access to Cue Health COVID-19 Remote testing and treatment for COVID-19 is the first listed.
NCT05655546 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05655546 about?
NCT05655546 is a clinical study titled "ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals". The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those...
What is the current status of trial NCT05655546?
This trial is currently terminated. It is a NA study. The enrollment target is 2,117 participants. The study started on 2022-12-22. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT05655546?
The interventions under investigation include: Access to Cue Health COVID-19 Remote testing and treatment for COVID-19 (OTHER).
Who is sponsoring clinical trial NCT05655546?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05655546's enrollment target sits among peer trials
2,117 49th of 2000 higher than 1,952 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI